Skip to content
ChickenStockChickenStock
ResearchFilings

AI English summary of an SEC filing — figures as filed

International Flavors & Fragrances logoInternational Flavors & Fragrances IFF

International Flavors & Fragrances said full-year 2024 net sales were $11.48 billion, flat compared to the prior year period, and on a comparable basis, currency neutral sales increased 6%.

8-KResults of Operations and Financial ConditionFiled Period of report Summary published (UTC)

Key points

AI summary
  1. International Flavors & Fragrances said full-year 2024 net sales were $11.48 billion, flat compared to the prior year period, and on a comparable basis, currency neutral sales increased 6%.

  2. The company disclosed that full-year 2024 income before taxes was $278 million, Q4 loss before taxes was $(115) million, full-year EPS was $0.95 and Q4 EPS was $(0.18).

  3. IFF said full-year 2024 cash flow from operations was $1,070 million, free cash flow, defined as cash flow from operations less capital expenditures, totaled $607 million, and net debt to credit-adjusted EBITDA at the end of Q4 was 3.8x.

  4. The company said full-year 2025 sales are expected to be in the range of $10.6 billion to $10.9 billion and adjusted operating EBITDA to be in the range of $2 billion to $2.15 billion. It added that the guidance includes 6 months of Pharma Solutions results with the divestiture assumed to close on June 30.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

Full-year 2024 sales $11.48 billion, comparable currency neutral basis up 6%

International Flavors & Fragrances said full-year 2024 net sales were $11.48 billion, flat compared to the prior year period, and on a comparable basis, currency neutral sales increased 6%.

Source · Based on the filing body and exhibits

Full-year income before taxes $278 million, Q4 loss before taxes $(115) million

The company disclosed that full-year 2024 income before taxes was $278 million, Q4 loss before taxes was $(115) million, full-year EPS was $0.95 and Q4 EPS was $(0.18).

Source · Based on the filing body and exhibits

Full-year operating cash flow $1,070 million, free cash flow $607 million

IFF said full-year 2024 cash flow from operations was $1,070 million, free cash flow, defined as cash flow from operations less capital expenditures, totaled $607 million, and net debt to credit-adjusted EBITDA at the end of Q4 was 3.8x.

Source · Based on the filing body and exhibits

2025 guidance: sales $10.6 billion–$10.9 billion, adjusted operating EBITDA $2 billion–$2.15 billion

The company said full-year 2025 sales are expected to be in the range of $10.6 billion to $10.9 billion and adjusted operating EBITDA to be in the range of $2 billion to $2.15 billion. It added that the guidance includes 6 months of Pharma Solutions results with the divestiture assumed to close on June 30.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

Source: SEC EDGAR (U.S. Securities and Exchange Commission). Item captions are the SEC's. The summary is for reference only and is not investment advice.